Thermo Fisher Scientific today announced that the company has entered into a definitive agreement to acquire Solventum’s Purification & Filtration business for approximately $4.1 billion in cash.
Solventum’s Purification & Filtration business is a provider of purification and filtration technologies used in the production of biologics as well as in medical technologies and industrial applications. The Solventum business operates globally with sites across the Americas, Europe, the Middle East, Africa, and the Asia-Pacific region, and has approximately 2,500 employees. In 2024, Solventum’s Purification & Filtration business generated approximately $1 billion of revenue.
Solventum’s filtration portfolio broadens Thermo Fisher’s capabilities in the development and manufacturing of biologics, spanning upstream and downstream workflows.
The transaction is expected to be completed by the end of 2025 and is subject to customary closing conditions and regulatory approvals. Once the transaction closes, Solventum’s Purification & Filtration business will become part of Thermo Fisher's Life Sciences Solutions segment.
